Quoin Pharmaceuticals Ltd. announced on October 6, 2026, that a peer-reviewed manuscript detailing the mechanism of action and clinical application of its investigational drug QRX003 has been accepted for publication in Dermatology and Therapy. The company stated that the paper, titled “An Investigational Mechanism-Informed Therapy for Netherton Syndrome: Introduction to QRX003 and a Pediatric Compassionate-Use Case Report,” highlights clinical experience from Professor Alan Irvine, consultant dermatologist at Children’s Health Ireland and professor of dermatology at Trinity College Dublin.
Clinical Case Report Details Pediatric Treatment Outcomes
The accepted manuscript features a case report from Professor Irvine detailing the treatment of a pediatric patient under Quoin’s Pediatric Compassionate Use Program. According to the company, the topical serine protease inhibitor lotion led to fully healed skin and the complete elimination of pruritus, or itch. The patient experienced zero nightly sleep disturbances as a result and showed a significant reduction in the need for all previously required medications. Quoin reported in June that four of six pediatric patients in the Compassionate Use Program were classified as improved or significantly improved from baseline, with no treatment-related adverse events reported.
Phase 2/3 Clinical Study and Regulatory Designations
In August, Quoin reported positive interim results from its ongoing Phase 2/3 study, designated CL-QRX003-004, evaluating the 4% QRX003 lotion in patients with Netherton Syndrome. An interim analysis of the first six participants to complete 12 weeks of treatment showed that four of the six, or 66.7%, achieved the primary endpoint of a 1-grade or greater improvement in Investigator Global Assessment, with a p-value of 0.0087 against a pre-specified alpha of 0.0215. QRX003 has earned Orphan Drug, Rare Pediatric Disease, and Fast Track designations from the U.S. Food and Drug Administration, alongside Orphan Drug Designation in the European Union and Japan.
SPINK5 Mutations Cause Rare Genetic Skin Disorder
Netherton Syndrome is a rare genetic skin disorder caused by mutations in the SPINK5 gene. The condition causes impaired skin barrier function, persistent inflammation, and elevated serine protease activity in the skin. There are currently no approved therapies in the United States specifically indicated for Netherton Syndrome, leaving a high unmet medical need for affected patients, families, and care teams.
Frequently Asked Questions About QRX003
What is QRX003?
QRX003 is an investigational topical serine protease inhibitor lotion developed by Quoin Pharmaceuticals to treat rare and orphan skin diseases, including Netherton Syndrome.
What did the peer-reviewed paper in Dermatology and Therapy evaluate?
The accepted manuscript introduces the mechanism of action of QRX003 and presents a case report from Professor Alan Irvine regarding a pediatric patient treated under Quoin’s Compassionate Use Program.
What are the current regulatory statuses of QRX003?
QRX003 holds Orphan Drug, Rare Pediatric Disease, and Fast Track designations from the U.S. FDA, as well as Orphan Drug Designation in both the European Union and Japan.
Worth a look